Scientists conducted a study to predict how a new experimental cancer drug, called TAK-500, might behave in people. They did this by creating a computer model. The model used data from studies in monkeys and from a related antibody that had been tested in humans. The goal was to estimate how the drug would be processed in the body, which helps plan the first human trials.
The main finding from the model was a prediction about how the drug is cleared from the body. The simulations suggested that as the dose of TAK-500 increases, the rate at which the body clears the drug decreases. The model also estimated how long different parts of the drug might stay in the body, with half-lives ranging from about 30 to 118 hours.
It is very important to understand what this study does and does not show. This was not a clinical trial in people with cancer. No one received TAK-500 in this study. The results are predictions from a computer model, not actual measurements from patients. The model's predictions need to be confirmed in real human studies, which are planned or underway. For now, this research provides a helpful framework for scientists to design those first human trials safely.